Evogene completes $4.5 m research expansion
Israeli genomics company Evogene (Rehovot) has completed a $4.5 million, two-stage expansion programme of its R&D facilities that sees a 50% increase in its gene validation and plant growth capacity. Stage one included reconstruction of existing facilities and the addition of a new 1,100 m 2 molecular and tissue culture laboratory, with the second stage focusing on a doubling in area of Evogene's greenhouse site at Gezer. The new laboratories are equipped with custom tailored automated instruments for lab processes, with emphasis on cost optimisation, international environmental safety standards and energy savings. The new facilities will substantially increase the amount and type of research activities that the company can undertake with its proprietary Athlete, EvoBreed and Gene2product computational genomic platforms, the company notes. It is able to clone, transform to model plants and validate over 1,000 genes per year, thus providing the capacity for continuing rapid growth and expansion, it adds.